Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AngioDynamics gets carte blanche to market spider vein therapy in US:

This article was originally published in Clinica

Executive Summary

AngioDynamics, the developer of minimally-invasive devices for treating peripheral vascular conditions, is to gain at least $3m in additional sales of its sclerotherapy product Sotradecol, after amending its distribution agreement with the product's Quebec, Canada-based developer Bioniche Pharma. Under the terms of the new contract, Queensbury, New York-based AngioDynamic can now sell Sotradecol - said to be the only sodium tetradecyl sulfate injection approved by the FDA for treating spider veins - in all markets including doctors of all specialties, hospital pharmacies, group purchasing organisations and wholesalers. Previously, the company was limited to selling the compound to interventional radiologists, vascular and general surgeons and doctors specialising in certain areas.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT052316

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel